Faculty profile

Lucy Gilbert

ResearcherObstetrics and GynecologyMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Lucy Gilbert

Researcher

Obstetrics and Gynecology

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
63 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

108

Publications

251

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Early Detection Of Ovarian Cancer Reducing False Positive Results Triage Of Symptomatic Patients

Latest papers

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Gynecologic oncology · 2026
Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological features.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
Real-world uptake of Lynch syndrome testing among patients with mismatch repair-deficient endometrial cancer in Québec.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC · 2026

All 108 publications

Latest funding

A prospective study of risk stratification with epigenetic markers to improve clinical management of cervical precancerous lesions
CIHR · 2024 · Co-investigator
$100,000
Diagnosing Ovarian Cancer Early (DOvE)by targeting symptomatic women
CIHR · 2012 · Nominated PI
$1,404,691
Towards the identification of optimal predictors of surgical complications in elderly cancer patients: A Pilot Study
CIHR · 2009 · Principal investigator
$86,235

All 3 grants and awards

108 publications.

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Powell MA, Roed H, Willmott LJ, Cibula D, Black D, Valabrega G, Sharma S, Kommoss S, Landrum LM, Boere I, Mathews C, Sukhin V, Gold MA, Lundgren C, Gill SE, Gilbert L, Cass I, Edelson MI, Buscema J, Nevadunsky NS, Ring K, Pothuri B, Eshed HD, McCourt C, Coleman RL, Grimshaw M, Austin L, Zajac M, Slomovitz B, Nøttrup T

Gynecologic oncology2026

DOI: 10.1016/j.ygyno.2026.05.008 PMID: 42215378

Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological features.

Hanna K, Levin G, Al Nasir M, Lacouline-Boulanger R, Shahbazian L, Diwan SS, Li J, Hamidi D, Stephan L, Hmimas M, Zhang N, Nathalie Nguyen PN, Richer L, Jacob K, Gomez A, Ribeiro R, Mandilaras V, Bernard L, Zeng X, Soslow RA, Gilbert L, Annie Leung SO, Tessier-Cloutier B

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104690 PMID: 42091345

Real-world uptake of Lynch syndrome testing among patients with mismatch repair-deficient endometrial cancer in Québec.

Eiley E, Levin G, Gilbert L, Ribeiro R, Leung A, Bernard L, Skolnik D, Ganesu B, Zeng X

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC2026

DOI: 10.1016/j.jogc.2026.103516 PMID: 42705461

Late metastatic recurrence of stage IA1 cervical cancer 12 years after minimally invasive radical hysterectomy.

Almsafi T, Ribeiro R, Gilbert L, Leung SOA

Journal of minimally invasive gynecology2026

DOI: 10.1016/j.jmig.2026.08.007 PMID: 42600682

Dexamethasone-associated hyperglycemia during chemotherapy in endometrial and ovarian cancer: a retrospective study.

Spicer K, Sánchez MC, Levin G, Ribeiro R, Zeng X, Bernard L, Mandilaras V, Gilbert L, Leung SOA

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104974 PMID: 42680636

Exploring the association between homologous recombination status, KELIM, and resectability in high-grade serous ovarian cancer.

Castrillón Sánchez M, Levin G, Shahbazian L, Ribeiro R, Zeng X, Bernard L, Tessier-Cloutier B, Gilbert L, Leung SOA

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104948 PMID: 42642281

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Powell MA, Ghamande S, Hanker LC, Black D, Raaschou-Jensen N, Gilbert L, Cibula D, Secord AA, Oaknin A, Holloway RW, Mathiesen HF, Buscema J, Kristeleit R, Sharma S, Boere IA, Slomovitz B, Gennigens C, Coleman RL, Heitz F, Barlin JN, Mavrichev S, Berek J, Bermejo-Pérez MJ, Weberpals J, Savarese A, Maret S, Yablonski K, Schroyer R, Austin L, Valabrega G, Nøttrup T

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104774 PMID: 42391799

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vergote I, Cibula D, Powell M, Laenen A, Nieuwenhuysen EV, Topuz S, González-Martín A, Fujiwara K, Safina S, Bagaméri A, Oliver M, Lee JY, Salutari V, Korach J, Lu CH, Mądry R, Vulsteke C, Colombo N, Sehouli J, Klat J, Ruiz EY, Gilbert L, Pautier P, Pardo B, Kridelka F, Wei J, Toker S, Yamada K, Coleman RL, ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators

The Lancet. Oncology2026

DOI: 10.1016/s1470-2045(26)00223-8 PMID: 42705254

Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis.

Levin G, Gilbert L, Monk BJ, Ribeiro R, Scalia P, Meyer R, Coleman RL

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104710 PMID: 42202504

Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.

Levin G, Eiley E, Gilbert L, Monk BJ, Coleman RL, Slomovitz BM, Ribeiro R, Meyer R, Skolnik D, Ramirez PT

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104744 PMID: 42172953

Something wrong or missing on this profile? Suggest a correction

Lucy Gilbert

Research

Latest papers

Latest funding

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological features.

Real-world uptake of Lynch syndrome testing among patients with mismatch repair-deficient endometrial cancer in Qu&#xe9;bec.

Late metastatic recurrence of stage IA1 cervical cancer 12 years after minimally invasive radical hysterectomy.

Dexamethasone-associated hyperglycemia during chemotherapy in endometrial and ovarian cancer: a retrospective study.

Exploring the association between homologous recombination status, KELIM, and resectability in high-grade serous ovarian cancer.

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis.

Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.

A prospective study of risk stratification with epigenetic markers to improve clinical management of cervical precancerous lesions

Diagnosing Ovarian Cancer Early (DOvE)by targeting symptomatic women

Towards the identification of optimal predictors of surgical complications in elderly cancer patients: A Pilot Study

Frequent collaborators

Anita Koushik

Anita Koushik

Joanne Alfieri

Michal Abrahamowicz

Stephanie Lheureux

Jack Siemiatycki

Olga Basso

Vikki Ho

Stephen Welch

Rima Slim

Todd Lee

Salman Qureshi

Anna Spreafico

Josee-Lyne Ethier

Caroline Reinhold

Janice Kwon

Thierry Muanza

Amit Oza

Tien Le

Tracy Stockley

Xuan Li

Martin Chasen

Nidhi Kumar Tyagi

Real-world uptake of Lynch syndrome testing among patients with mismatch repair-deficient endometrial cancer in Québec.